Xenetic Biosciences (XBIO) AI Stock Analysis

347 Followers

Xenetic Biosciences

(NASDAQ:XBIO)

Select Model

Rating:46Neutral

Price Target:$1.50▼(-9.64% Downside)

Action:reiterated

Date:11/13/26

The score is held down primarily by weak financial performance (ongoing losses and cash burn despite low debt) and bearish technicals (price below key moving averages with negative MACD). The proposed Santersus acquisition provides a strategic upside catalyst, but its all-stock, highly dilutive structure and the company’s current lack of profitability limit the overall rating.

Positive Factors

Debt-free balance sheetEssentially no debt gives Xenetic greater financial flexibility than a highly leveraged biotechnology company. The absence of a meaningful interest burden preserves resources for research and development, while reducing refinancing pressure if operating losses continue over the next several quarters.

Negative Factors

Persistent cash burnContinuing negative operating and free cash flow means Xenetic is not yet funding its activities internally. Ongoing cash consumption can require additional financing, constrain development choices, and increase dependence on successful transactions or capital raising while the pipeline advances.

Xenetic Biosciences (XBIO) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $3.89M
Dividend Yield: ―
Average Volume (3M): 74.24K
Price to Earnings (P/E): -1.1
Beta (1Y): 0.65
Revenue Growth: 3.50%
EPS Growth: 22.76%
Country: US
Employees: 2
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Xenetic Biosciences Business Overview & Revenue Model

Company Description

Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily concentrating on the development of XCART. This cutting-edge personalized chimeric antigen receptor T cell (CAR T) platform is specifically engineered to identify and attack di...

Xenetic Biosciences Financial Statement Overview

Summary

Financials are pressured by persistent losses and cash burn (TTM net margin ~-76%, TTM operating/free cash flow about -$2.3M). Balance-sheet leverage is a strength with essentially no debt (reducing solvency risk), but equity has fallen materially over time and returns on equity remain negative, keeping overall financial quality below average.

Income Statement

18Very Negative

Balance Sheet

62Positive

Cash Flow

22Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.96M	2.98M	2.50M	2.54M	1.71M	1.16M
Gross Profit	494.67K	2.98M	2.50M	2.54M	1.71M	1.16M
EBITDA	-3.66M	-2.68M	-3.81M	-4.13M	-6.53M	-5.61M
Net Income	-3.66M	-2.68M	-3.96M	-4.13M	-6.55M	-5.65M
Balance Sheet
Total Assets	6.32M	8.36M	6.90M	10.61M	14.72M	19.82M
Cash, Cash Equivalents and Short-Term Investments	5.81M	7.88M	6.17M	8.98M	13.10M	18.24M
Total Debt	0	0	0	0	0	27.04K
Total Liabilities	1.90M	968.02K	894.26K	809.59K	1.07M	1.42M
Stockholders Equity	4.41M	7.40M	6.01M	9.80M	13.65M	18.39M
Cash Flow
Free Cash Flow	-2.32M	-2.29M	-2.82M	-4.11M	-5.15M	-4.74M
Operating Cash Flow	-2.32M	-2.29M	-2.82M	-4.11M	-4.65M	-4.74M
Investing Cash Flow	0	0	0	0	-500.00K	0
Financing Cash Flow	4.00M	4.00M	0	0	0	11.45M

Xenetic Biosciences Technical Analysis

Technical Analysis SentimentNegative

Last Price1.66

Price Trends

50DMA2.42Negative

100DMA2.77Negative

200DMA2.81Negative

Market Momentum

MACD-0.16Negative

RSI33.25Neutral

STOCH11.53Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XBIO, the sentiment is Negative. The current price of 1.66 is below the 20-day moving average (MA) of 1.91, below the 50-day MA of 2.42, and below the 200-day MA of 2.81, indicating a bearish trend. The MACD of -0.16 indicates Negative momentum. The RSI at 33.25 is Neutral, neither overbought nor oversold. The STOCH value of 11.53 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XBIO.

Xenetic Biosciences Risk Analysis

Xenetic Biosciences disclosed 67 risk factors in its most recent earnings report. Xenetic Biosciences reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks

1.Actions of activist shareholders could cause us to incur substantial costs, divert management's attention and resources, and have an adverse effect on our business.Q4, 2023

2.The Reverse Stock Split may decrease the liquidity of our common shares.Q4, 2023

3.Market conditions and changing circumstances, some of which may be beyond our control, could impair our ability to access our existing cash, cash equivalents and investments and to timely pay collaborators and others.Q4, 2023

Xenetic Biosciences Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

XBIO against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
XBIO	46Neutral	$3.89M	-1.05	-58.96%	―	3.50%	22.76%
APRE	43Neutral	$6.24M	-0.59	-44.26%	―	-99.32%	67.31%
HCWB	42Neutral	$1.79M	-0.01	-142.16%	―	707.02%	70.52%

* Healthcare Sector Average

Performance Comparison

XBIO and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
XBIO	Xenetic Biosciences, Inc.	1.66	-0.83	-33.33%
ERNA	Eterna Therapeutics Inc.	1.68	-36.07	-95.55%
APRE	Aprea Therapeutics, Inc.	0.42	-0.77	-65.04%
HCWB	Hcw Biologics, Inc.	0.77	-17.59	-95.79%

Xenetic Biosciences Corporate Events

Business Operations and StrategyM&A TransactionsRegulatory Filings and Compliance

Xenetic Updates Investors on Santersus Share Exchange Plans

Neutral

Sep 23, 2026

On September 23, 2026, Xenetic Biosciences released an updated investor presentation tied to its pending share exchange transaction with Swiss-based Santersus AG, a deal first announced on September 16, 2026. The company also confirmed it will file a...

Business Operations and StrategyM&A TransactionsRegulatory Filings and Compliance

Xenetic Biosciences to Acquire Santersus AG in Merger

Positive

Sep 16, 2026

On September 14, 2026, Xenetic Biosciences agreed to acquire all outstanding shares of Swiss medical device group Santersus AG via an all-stock share exchange that will make Santersus a wholly owned subsidiary, with its investors owning roughly 85 pe...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026

Xenetic Biosciences AI Stock Analysis